GGI
TEVA icon

Godsey & Gibb Inc’s Teva Pharmaceuticals TEVA Stock Holding History

Godsey & Gibb Inc’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,000
Closed -$20.9K – 419
2023
Q4 		$20.9K Buy
+2,000
New +$18.7K ﹤0.01% 218

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Godsey & Gibb Inc's TEVA Position: Q1 2024 in Review

Godsey & Gibb Inc sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 2,000 shares — an estimated $20.9K sold.

Godsey & Gibb Inc first reported a position in TEVA in Q4 2023 and held it in 1 quarter. The position peaked at $20.9K in Q4 2023. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Godsey & Gibb Inc reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Godsey & Gibb Inc sold 2,000 Teva Pharmaceuticals shares in Q1 2024, an estimated $20.9K.
  • Godsey & Gibb Inc first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Godsey & Gibb Inc's Teva Pharmaceuticals position peaked at $20.9K in Q4 2023.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Godsey & Gibb Inc's 13F filing for Q1 2024, filed 23 Apr 2024.